Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis Against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Cinnamates
/ metabolism
Humans
Melanoma
/ drug therapy
Melanoma, Amelanotic
/ drug therapy
Molecular Docking Simulation
Plant Extracts
/ pharmacology
Polygonaceae
/ metabolism
Proto-Oncogene Proteins B-raf
/ genetics
Rhizome
/ chemistry
cell death
cytotoxicity
giant knotweed
hydroxycinnamic esters
kinases
melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Jun 2020
29 Jun 2020
Historique:
received:
21
05
2020
revised:
21
06
2020
accepted:
25
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Vanicosides A and B are the esters of hydroxycinnamic acids with sucrose, occurring in a few plant species from the Polygonaceae family. So far, vanicosides A and B have not been evaluated for anticancer activity against human malignant melanoma. In this study, we tested these two natural products, isolated from Reynoutria sachalinensis rhizomes, against two human melanoma cell lines (amelanotic C32 cell line and melanotic A375 cell line, both bearing endogenous BRAFV600E mutation) and two normal human cell lines-keratinocytes (HaCaT) and the primary fibroblast line. Additionally, a molecular docking of vanicoside A and vanicoside B with selected targets involved in melanoma progression was performed. Cell viability was studied using an MTT assay. A RealTime-Glo™ Annexin V Apoptosis and Necrosis assay was used for monitoring programmed cell death (PCD). Vanicoside A demonstrated strong cytotoxicity against the amelanotic C32 cell line (viability of the C32 cell line was decreased to 55% after 72 h incubation with 5.0 µM of vanicoside A), significantly stronger than vanicoside B. This stronger cytotoxic activity can be attributed to an additional acetyl group in vanicoside A. No significant differences in the cytotoxicity of vanicosides were observed against the less sensitive A375 cell line. Moreover, vanicosides caused the death of melanoma cells at concentrations from 2.5 to 50 µM, without harming the primary fibroblast line. The keratinocyte cell line (HaCaT) was more sensitive to vanicosides than fibroblasts, showing a clear decrease in viability after incubation with 25 µM of vanicoside A as well as a significant phosphatidylserine (PS) exposure, but without a measurable cell death-associated fluorescence. Vanicosides induced an apoptotic death pathway in melanoma cell lines, but because of the initial loss of cell membrane integrity, an additional cell death mechanism might be involved like permeability transition pore (PTP)-mediated necrosis that needs to be explored in the future. Molecular docking indicated that both compounds bind to the active site of the BRAFV600E kinase and MEK-1 kinase; further experiments on their specific inhibitory activity of these targets should be considered.
Identifiants
pubmed: 32610527
pii: ijms21134611
doi: 10.3390/ijms21134611
pmc: PMC7370030
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Cinnamates
0
Plant Extracts
0
vanicoside B
155179-21-8
vanicoside A
155179-22-9
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
ID : STM.D030.20.009
Organisme : Ministerstwo Nauki i Szkolnictwa Wyższego
ID : 96/E-394/SPUB/SP/2019
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biochem Biophys Res Commun. 2015 Nov 27;467(4):1006-11
pubmed: 26456656
Bioorg Chem. 2019 Oct;91:103125
pubmed: 31401373
Cancer Biol Ther. 2013 Oct 1;14(10):907-15
pubmed: 23917379
Bioelectrochemistry. 2018 Oct;123:255-259
pubmed: 29929176
Cancer Res. 2014 Dec 1;74(23):7037-47
pubmed: 25297634
Melanoma Res. 2019 Jun;29(3):221-230
pubmed: 30672881
Nature. 2010 Sep 30;467(7315):596-9
pubmed: 20823850
Molecules. 2019 Mar 21;24(6):
pubmed: 30901974
Biochim Biophys Acta. 2016 Oct;1860(10):2107-21
pubmed: 27369735
Arch Pharm Res. 2005 Oct;28(10):1183-9
pubmed: 16276977
Oncotarget. 2014 Apr 15;5(7):1701-52
pubmed: 24743024
Bioorg Med Chem. 2018 Dec 15;26(23-24):6015-6022
pubmed: 30446440
J Struct Biol. 2012 Feb;177(2):329-34
pubmed: 22245778
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
J Cell Physiol. 2020 Apr 23;:
pubmed: 32324275
Pigment Cell Melanoma Res. 2018 Jan;31(1):11-30
pubmed: 29049843
Nat Prod Res. 2017 Aug;31(15):1725-1732
pubmed: 28278632
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
Cytotechnology. 2016 Mar;68(2):223-8
pubmed: 25060709
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Molecules. 2016 Oct 24;21(10):
pubmed: 27783048
Br J Cancer. 2016 Mar 29;114(7):801-8
pubmed: 26924424
Int J Mol Sci. 2020 Jan 20;21(2):
pubmed: 31968672
Evid Based Complement Alternat Med. 2015;2015:512675
pubmed: 25861364
Front Oncol. 2019 Apr 17;9:268
pubmed: 31058079
Anticancer Res. 2020 May;40(5):2613-2625
pubmed: 32366406
Chem Biol Drug Des. 2016 Oct;88(4):485-97
pubmed: 27115708
PLoS One. 2017 Jun 19;12(6):e0179936
pubmed: 28628649
Med Sci Monit. 2019 May 04;25:3279-3287
pubmed: 31053701
Metabolites. 2015 Sep 30;5(4):571-600
pubmed: 26437434
Arch Pharm Res. 2017 Jun;40(6):704-712
pubmed: 28501973
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
pubmed: 18287029
Int J Mol Sci. 2018 May 25;19(6):
pubmed: 29799486
Toxicol Lett. 2017 Jan 4;265:117-130
pubmed: 27890807
Apoptosis. 2019 Feb;24(1-2):184-197
pubmed: 30498998
J Nat Prod. 2019 Nov 22;82(11):3140-3149
pubmed: 31622095
Int J Mol Sci. 2020 May 21;21(10):
pubmed: 32455738
Photochem Photobiol. 1996 Aug;64(2):375-81
pubmed: 8760577
J Nat Prod. 1994 Feb;57(2):236-42
pubmed: 8176400
Planta Med. 2018 Oct;84(15):1118-1126
pubmed: 29672819